Recent Advances in CRISPR/Cas Systems for Respiratory Pathogen Diagnostics
Viruses · 2026
DOI: 10.3390/v18080870 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Viruses, 2026. Verfasst von Yujie Dai und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, The Affiliated Yixing Clinical School of Medical School of Yangzhou University, Yixing 214200, China. Hauptthemen laut MEDLINE: CRISPR-Cas Systems, Respiratory Tract Infections, Molecular Diagnostic Techniques. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 88 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Xuhua Mao, Wuxi Health Committee.
Abstract (Originalsprache)
Early, rapid, and accurate detection is essential for clinical management and epidemiological control of acute respiratory infections caused by pathogens. Traditional testing methods such as microbial culture, serological testing, and PCR are restrictive in terms of operation and logistics and are therefore not easily used in point-of-care settings. The CRISPR/Cas system is an adaptive prokaryotic immune system composed of clustered regularly interspaced short palindromic repeats and their associated proteins, which has been used as a nucleic acid diagnostic platform with programmable sequence-specific target recognition and signal-amplifying collateral cleavage activity. Existing reviews have mostly focused on the classification of Cas enzymes or amplification strategies; in this review, a pathogen-centric approach was taken, covering viral pathogens (SARS-CoV-2, influenza virus, RSV, HAdV and VZV), bacterial pathogens (Mycobacterium tuberculosis, Streptococcus pneumoniae, Mycoplasma pneumoniae and Staphylococcus aureus) and fungal pathogens (Aspergillus fumigatus and Pneumocystis jirovecii). Key technological advances, such as isothermal amplification coupling, single-vessel integrated reaction designs, amplification-free digital detection, and electrochemical biosensor integration, are evaluated for Cas9-, Cas12-, and Cas13-based systems, with their mechanistic bases outlined. The current challenges that hinder clinical translation, such as sample matrix interference, multiple signal cross-talk, crRNA off-target effects, and the lack of large-scale validation studies, are critically assessed. At the same time, future pathways for portable, integrated, and inexpensive diagnostic platforms are suggested.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Laboratory, The Affiliated Yixing Clinical School of Medical School of Yangzhou University, Yixing 214200, China.
- Department of Pediatrics, The Affiliated Yixing Clinical School of Medical School of Yangzhou University, Yixing 214200, China.
- Department of Clinical Nutrition, The Affiliated Yixing Clinical School of Medical School of Yangzhou University, Yixing 214200, China.
Förderung
- Xuhua Mao
- Wuxi Health Committee
Zitieren
APA
Dai, Y., Xia, L., Yang, Y., Qiao, G., Jin, X., & Mao, X. (2026). Recent Advances in CRISPR/Cas Systems for Respiratory Pathogen Diagnostics. Viruses. https://doi.org/10.3390/v18080870
Vancouver
Dai Y, Xia L, Yang Y, Qiao G, Jin X, Mao X. Recent Advances in CRISPR/Cas Systems for Respiratory Pathogen Diagnostics. Viruses. 2026. doi:10.3390/v18080870
BibTeX
@article{Dai2026,
author = {Dai, Yujie and Xia, Lingyun and Yang, Yufei and Qiao, Guohong and Jin, Xing and Mao, Xuhua},
title = {Recent Advances in CRISPR/Cas Systems for Respiratory Pathogen Diagnostics},
journal = {Viruses},
year = {2026},
doi = {10.3390/v18080870}
}
EUVIMED